Bofutrelvir NEW
| Price | $198 | $572 | $813 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-06 |
Product Details
| Product Name: Bofutrelvir | CAS No.: 2103278-86-8 |
| Purity: 99.92% | Supply Ability: 10g |
| Release date: 2026/05/06 |
Product Introduction
Bioactivity
| Name | Bofutrelvir |
| Description | Bofutrelvir (FB2001) is a SARS-CoV-2 3CL protease inhibitor with antiviral activity for the study of novel coronavirus pneumonia (COVID-19) infections. |
| In vitro | MPro Inhibitor 11a (24 hours) exhibits in vitro inhibitory activity against SARS-CoV-2 and its variants when combined with remdesivir treatment[1]. |
| In vivo | In K18-hACE2 mice infected with the SARS-CoV-2 Delta variant, MPro Inhibitor 11a (100 and 200 mg/kg; intraperitoneal injection; administered once daily at 100 and 200 mg/kg on day 0 and twice daily on days 1, 2, and 3 for 4 consecutive days) demonstrated a dose-dependent efficacy against lung viral titers, effectively reducing lung viral loads[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 30 mg/mL (66.29 mM), Sonication is recommended. DMF : 30 mg/mL (66.29 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (7.29 mM), Sonication is recommended. DMSO : 145 mg/mL (320.41 mM), Sonication is recommended. |
| Keywords | SARS-CoV-2 3CL | SARSCoV |
| Inhibitors Related | Nirmatrelvir | EIDD-1931 | Remdesivir | Molnupiravir | Silymarin | Umifenovir hydrochloride | Hydroxychloroquine | Ritonavir | Chloroquine phosphate | Dexamethasone acetate | α-Cyclodextrin | Dexamethasone |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Protease Inhibitor Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Infection Compound Library | Anti-COVID-19 Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY